Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-12), Wave Life Sciences's 1-Year Sharpe Ratio is 0.20.
Wave Life Sciences (NAS:WVE) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Wave Life Sciences 1-Year Sharpe Ratio Related Terms
WVE vs FBRX, SVRA, SPTX: 1-Year Sharpe Ratio Comparison
For the Biotechnology subindustry, Wave Life Sciences's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wave Life Sciences 1-Year Sharpe Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wave Life Sciences's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Wave Life Sciences's 1-Year Sharpe Ratio falls into.
Wave Life Sciences 1-Year Sharpe Ratio Calculation
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Wave Life Sciences (WVE) has a 1-Year Sharpe Ratio of 0.20 as of Aug. 12, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Wave Life Sciences and its competitors.
Is Wave Life Sciences' 1-Year Sharpe Ratio too high?
Wave Life Sciences' current 1-Year Sharpe Ratio is 0.20. Overall, Wave Life Sciences has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' 1-Year Sharpe Ratio compare to FBRX and SVRA?
Wave Life Sciences' 1-Year Sharpe Ratio of 0.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Wave Life Sciences and its competitors. Wave Life Sciences's current 1-Year Sharpe Ratio is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Wave Life Sciences (WVE) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $5.04 — trading 14.3% above its estimated fair value. The current 1-Year Sharpe Ratio is 0.20. Wave Life Sciences' overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Wave Life Sciences (WVE), the current 1-Year Sharpe Ratio is 0.20 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wave Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued.
The current stock price of $5.04 is trading 14.3% above its estimated GF Value™ of $4.41.
GuruFocus considers Wave Life Sciences to be Modestly Overvalued.
Key valuation signals for WVE:
1-Year Sharpe Ratio: 0.20
GF Value™: $4.41 vs. price of $5.04 (14.3% above fair value)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
58GF Score
Get the complete analysis for WVE
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
